This 30-minute CME-accredited program, hosted by John Kuruvilla, MD, discusses best practices for talking to patients with hematologic malignancies about possibly participating in clinical trials.
Jointly Provided by American Academy of CME and CheckRare CE.

Support for this accredited continuing education activity has been made possible through educational grant from Merck.

Estimated time to complete: 0.5 hours
 
Start date: November 30, 2024
End date: November 30, 2025
  
Activity Faculty
John Kuruvilla, MD
Hematologist / Clinical Investigator
Princess Margaret Cancer Centre
Professor of Medicine
University of Toronto
 
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in hematology-oncology. Other healthcare providers, including NPs and PAs, may also participate.
 
Learning Objectives
After participating in the activity, learners should be better able to
- Describe the importance of clinical trials in furthering the science of hematologic malignancies treatment.

- Describe and utilize best practices for engaging patients in shared decision making regarding clinical trial participation.
 
Accreditation and Credit Designation
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 
Physicians
American Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Other HCPs
Other members of the care team will receive a certificate of participation.
 
Disclosure Statement
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure of relevant financial relationships are as follows:
 
Faculty Educator/Planner
Dr. Kuruvilla discloses the following relevant financial relationships with ineligible companies:
Honoraria: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Beigene, Genmab, Gilead Sciences, GlaxoSmithKline, Incyte, Janssen, Karyopharm, Merck, Novartis, Pfizer, Roche, Seattle Genetics
Consultant: AbbVie, Bristol Myers Squibb, Gilead Sciences/Kite, Merck, Roche, Seattle Genetics
Grant/Research Support: AstraZeneca, Kite, Merck, Novartis, Roche
Data Safety Monitoring Board: Karyopharm
Planners for this activity have no relevant financial relationships with any ineligible companies.
 
This activity will not review off-label or investigational information.
 
The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
 Back to Episodes